AR115537A1 - Terapia combinada con una vacuna neoantigénica - Google Patents
Terapia combinada con una vacuna neoantigénicaInfo
- Publication number
- AR115537A1 AR115537A1 ARP190101629A ARP190101629A AR115537A1 AR 115537 A1 AR115537 A1 AR 115537A1 AR P190101629 A ARP190101629 A AR P190101629A AR P190101629 A ARP190101629 A AR P190101629A AR 115537 A1 AR115537 A1 AR 115537A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptide
- combined therapy
- neoepitope
- nivolumab
- ipilimumab
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 108091008874 T cell receptors Proteins 0.000 abstract 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 229960005386 ipilimumab Drugs 0.000 abstract 2
- 229960003301 nivolumab Drugs 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 229940123189 CD40 agonist Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000009826 neoplastic cell growth Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Un método para tratar o prevenir una neoplasia en un sujeto humano que lo necesita caracterizado porque comprende administrar a un sujeto que lo necesita: (a) un primer componente que comprende (i) un péptido que comprende un neoepitope de una proteína, (ii) un polinucleótido que codifica para el péptido, (iii) una o más CPA que comprenden el péptido o el polinucleótido que codifica para el péptido o (iv) un receptor de células T (TCR) específico del neoepitope en complejo con una proteína HLA; y (b) un segundo componente que comprende por lo menos dos inhibidores, en donde los al menos dos inhibidores comprenden: (i) nivolumab y un anticuerpo agonista anti-CD40, o (ii) nivolumab e ipilimumab, o (iii) ipilimumab y un anticuerpo agonista anti-CD40.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862684013P | 2018-06-12 | 2018-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR115537A1 true AR115537A1 (es) | 2021-01-27 |
Family
ID=68843592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190101629A AR115537A1 (es) | 2018-06-12 | 2019-06-12 | Terapia combinada con una vacuna neoantigénica |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210386856A1 (es) |
EP (1) | EP3807320A4 (es) |
AR (1) | AR115537A1 (es) |
TW (1) | TW202035446A (es) |
WO (1) | WO2019241306A2 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL295241A (en) * | 2020-02-10 | 2022-10-01 | Univ Johns Hopkins | Cancer immunotherapy using allogeneic and tumor-specific t-cell and cd4-cell transfusion |
WO2024020472A1 (en) * | 2022-07-20 | 2024-01-25 | Biontech Us Inc. | Combination therapy with neoantigen vaccine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG194701A1 (en) * | 2011-04-29 | 2013-12-30 | Apexigen Inc | Anti-cd40 antibodies and methods of use |
WO2015095811A2 (en) * | 2013-12-20 | 2015-06-25 | The Board Institute Inc. | Combination therapy with neoantigen vaccine |
CN106573981A (zh) * | 2014-08-12 | 2017-04-19 | 鳄鱼生物科学公司 | 利用抗cd40抗体的组合疗法 |
CN113791220A (zh) * | 2014-09-10 | 2021-12-14 | 豪夫迈·罗氏有限公司 | 免疫原性突变体肽筛选平台 |
-
2019
- 2019-06-11 WO PCT/US2019/036632 patent/WO2019241306A2/en unknown
- 2019-06-11 EP EP19820230.1A patent/EP3807320A4/en active Pending
- 2019-06-11 US US17/251,285 patent/US20210386856A1/en active Pending
- 2019-06-12 TW TW108120303A patent/TW202035446A/zh unknown
- 2019-06-12 AR ARP190101629A patent/AR115537A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3807320A4 (en) | 2022-03-23 |
US20210386856A1 (en) | 2021-12-16 |
EP3807320A2 (en) | 2021-04-21 |
TW202035446A (zh) | 2020-10-01 |
WO2019241306A3 (en) | 2020-01-23 |
WO2019241306A9 (en) | 2020-09-03 |
WO2019241306A2 (en) | 2019-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019010698A2 (es) | Vacunas de peptidos | |
CO2019009234A2 (es) | Composiciones terapéuticas inmunomoduladoras de arnm que codifican péptidos de activación de mutaciones oncogénicas | |
CL2021001744A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324) | |
BR112019003866A2 (pt) | adenovírus estimulado com fragmento de mab biespecífico com redirecionamento de células t (bite) | |
CY1125144T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης | |
CL2017002686A1 (es) | Métodos para tratar o prevenir dolor de cabeza por migraña | |
CL2020000498A1 (es) | Composiciones farmacéuticas que contienen anticuerpos contra la glicoproteína del virus ébola. (divisional solicitud 201701920) | |
CL2019003142A1 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso. | |
CL2018001611A1 (es) | Adenovirus del grupo b que codifica un anticuerpo o fragmento anti-tcr-complejo | |
BR112019022495A2 (pt) | Conjugados de anticorpo que compreendem agonista de receptor similar a toll e terapias de combinação | |
BR112018072915A2 (pt) | peptídeo cíclico isolado e composição farmacêutica | |
PH12018502652A1 (en) | Combination therapies | |
AR108468A1 (es) | POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS | |
CL2023002252A1 (es) | Un complejo novedoso que comprende un péptido penetrante de células, una carga y un agonista | |
AR099698A1 (es) | Anticuerpos contra el c5 que tienen farmacocinética mejorada | |
BR112016012506A8 (pt) | combinações farmacêuticas, seus usos, e uso de um portador de dados | |
AR107303A1 (es) | Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit | |
ECSP21038390A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr | |
BR112015021392A2 (pt) | uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas | |
EA201891946A1 (ru) | Коагонисты глюкагона и glp-1 для лечения ожирения | |
PE20161152A1 (es) | Anticuerpos y metodos de uso | |
CL2018000377A1 (es) | Mecanismo de resistencia a inhibidores de bromodominio bet | |
AR115537A1 (es) | Terapia combinada con una vacuna neoantigénica | |
MX2020004837A (es) | Inhibidores de la vía de adenosina para el tratamiento del cáncer. | |
AR111360A1 (es) | Tratamiento usando células t de receptor quimérico incorporando células t polifuncionales optimizadas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |